Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jan 14

PMID 33440683

Citations 7

Authors

Carmelo Gurnari

Maria Teresa Voso

Katia Girardi

Angela Mastronuzzi

Luisa Strocchio

Affiliations

Soon will be listed here.

Abstract

Acute promyelocytic leukemia (APL) represents a paradigm of precision medicine. Indeed, in the last decades, the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) completely revolutionized the therapeutic approach to this previously highly fatal disorder. This entirely chemotherapy-free treatment, which provided excellent survival rates, has been initially validated in adults and, recently, translated in the pediatric setting. This review summarizes currently available data on the use of ATRA and ATO combination in pediatric APL, providing a particular focus on peculiar issues and challenges, such as the occurrence of and death during induction (early death), as well as the advantage offered by the ATO/ATRA combination in sparing long-term .

Citing Articles

Sodium arsenite and arsenic trioxide differently affect the oxidative stress of lymphoblastoid cells: An intricate crosstalk between mitochondria, autophagy and cell death.

Rainey N, Armand A, Petit P PLoS One. 2024; 19(5):e0302701.

PMID: 38728286 PMC: 11086853. DOI: 10.1371/journal.pone.0302701.

Long-term experience in treatment of acute promyelocytic leukemia in Mexican children in a tertiary care hospital.

Murillo-Maldonado M, Galvan P, Ortega I, Morales F, Villegas L, Acosta E Front Oncol. 2023; 13:1286106.

PMID: 38023223 PMC: 10661391. DOI: 10.3389/fonc.2023.1286106.

Chemotherapy-free treatment for acute promyelocytic leukemia: the pediatric view of a revolutionary tale.

Masetti R, Muratore E, Leardini D, Baccelli F, Pession A, Prete A Front Oncol. 2023; 13:1135350.

PMID: 37124521 PMC: 10145906. DOI: 10.3389/fonc.2023.1135350.

Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.

Wang Q, Hussain L, Yu P, Yang C, Zhu C, Ma Y Acta Pharmacol Sin. 2022; 44(4):822-831.

PMID: 36216898 PMC: 10042863. DOI: 10.1038/s41401-022-01001-6.

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases.

Chin L, Kumana C, Kwong Y, Gill H Pharmaceutics. 2022; 14(9).

PMID: 36145693 PMC: 9504237. DOI: 10.3390/pharmaceutics14091945.

References

Lo-Coco F, Hasan S . Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014; 27(1):3-9. DOI: 10.1016/j.beha.2014.04.006. View

Rajpurkar M, Alonzo T, Wang Y, Gerbing R, Gamis A, Feusner J . Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631. J Pediatr Hematol Oncol. 2018; 41(1):51-55. PMC: 6419515. DOI: 10.1097/MPH.0000000000001280. View

Sanz M, Coco F, Martin G, Avvisati G, Rayon C, Barbui T . Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000; 96(4):1247-53. View

Zhang L, Zou Y, Chen Y, Guo Y, Yang W, Chen X . Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. BMC Cancer. 2018; 18(1):374. PMC: 5883545. DOI: 10.1186/s12885-018-4280-2. View

Gurnari C, Breccia M, Giuliano F, Scalzulli E, Divona M, Piciocchi A . Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters. Br J Haematol. 2020; 193(1):129-132. DOI: 10.1111/bjh.17018. View

Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S . PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia. 2016; 30(10):1987-1992. DOI: 10.1038/leu.2016.122. View

Strocchio L, Gurnari C, Santoro N, Putti M, Micalizzi C, Zecca M . Arsenic trioxide and all-trans retinoic acid treatment for childhood acute promyelocytic leukaemia. Br J Haematol. 2018; 185(2):360-363. DOI: 10.1111/bjh.15507. View

Sanz M, Montesinos P . Advances in the management of coagulopathy in acute promyelocytic leukemia. Thromb Res. 2020; 191 Suppl 1:S63-S67. DOI: 10.1016/S0049-3848(20)30399-6. View

Mazzarella L, Botteri E, Matthews A, Gatti E, Di Salvatore D, Bagnardi V . Obesity is a risk factor for acute promyelocytic leukemia: evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism. Haematologica. 2019; 105(6):1559-1566. PMC: 7271575. DOI: 10.3324/haematol.2019.223925. View

10.

Kwok C, Zeisig B, Dong S, So C . Forced homo-oligomerization of RARalpha leads to transformation of primary hematopoietic cells. Cancer Cell. 2006; 9(2):95-108. DOI: 10.1016/j.ccr.2006.01.005. View

11.

Rowley J, Golomb H, Dougherty C . 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977; 1(8010):549-50. DOI: 10.1016/s0140-6736(77)91415-5. View

12.

Breccia M, Mazzarella L, Bagnardi V, Disalvatore D, Loglisci G, Cimino G . Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood. 2011; 119(1):49-54. DOI: 10.1182/blood-2011-07-369595. View

13.

Zhu H, Hu J, Lo-Coco F, Jin J . The simpler, the better: oral arsenic for acute promyelocytic leukemia. Blood. 2019; 134(7):597-605. DOI: 10.1182/blood.2019000760. View

14.

Camacho L, Soignet S, Chanel S, Ho R, Heller G, Scheinberg D . Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000; 18(13):2620-5. DOI: 10.1200/JCO.2000.18.13.2620. View

15.

Friedman D, Liu G, Digre K . Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013; 81(13):1159-65. DOI: 10.1212/WNL.0b013e3182a55f17. View

16.

Ciangola G, Gurnari C, Paterno G, Mirabile M, Angelini M, Lavorgna S . STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype. Leuk Res. 2019; 78:21-23. DOI: 10.1016/j.leukres.2019.01.004. View

17.

Lehmann-Che J, Bally C, Letouze E, Berthier C, Yuan H, Jollivet F . Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia. Nat Commun. 2018; 9(1):2047. PMC: 5967331. DOI: 10.1038/s41467-018-04384-5. View

18.

Gomez S, Schuttenberg V, Armendariz H, Alba L, Martinez M, Fynn A . Childhood acute leukemia: a single institution experience in La Plata, Argentina. Med Pediatr Oncol. 2001; 36(3):383-5. DOI: 10.1002/mpo.1090. View

19.

Wells R, Catzavelos C, Kamel-Reid S . Fusion of retinoic acid receptor alpha to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nat Genet. 1997; 17(1):109-13. DOI: 10.1038/ng0997-109. View

20.

Adamson P, Bailey J, Pluda J, Poplack D, Bauza S, Murphy R . Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol. 1995; 13(5):1238-41. DOI: 10.1200/JCO.1995.13.5.1238. View